• Jan 20, 2021

    Critical cancer treatment reaches more people in Africa

    Covid-19 has delayed the diagnosis and treatment of cancer in hospitals around the world. Lockdowns and travel restrictions have prevented the shipping, installation, clinical use and servicing of life-saving radiation therapy systems. Despite this, the West African country Togo has been remarkable in launching the county’s first linac. According to the...

  • Jan 06, 2021

    Paper on first Elekta MR-Linac patient treatments earns award for most citations in physics journal

    The intense interest in the potential of MR-guided radiation therapy spurred researchers to cite – in great numbers in Physics in Medicine & Biology (PMB) – a paper describing the 2017 first-in-human proof-of-concept study involving the prototype of Elekta Unity, the world’s first high-field (1.5T) MR-Linac. The 217 citations of...

  • Dec 21, 2020

    Serpil looks ahead to new beginnings

    When Serpil received her cancer diagnosis at 38, her thoughts immediately turned to her young children. Would her family be able to continue exploring cities, going on picnics or visiting her relatives in Turkey or her husband’s in Greece? And how would Covid-19 affect her access to cancer care? Serpil’s...

  • Nov 19, 2020

    Elekta Unity patients can sigh a breath of relief with new imaging upgrade

    Elekta recently received CE mark for the use of 3D VANE XD It was already the most advanced magnetic resonance radiation therapy (MR/RT) system in the world when launched in 2018, nevertheless, Elekta’s MR-Linac, Elekta Unity, continues to evolve, and further sets us apart from our competitors. Motion related image...

  • Nov 09, 2020

    How Elekta’s Thiago Ramos overcame cancer

    “I was initially treated with chemotherapy, the most common treatment for Hodgkin lymphoma. Unfortunately, the cancer did not respond well so my doctor convinced me that a bone marrow transplant would be our best bet. But first we needed to use radiotherapy to reduce the lymph nodes as much as...